

**Furosemide Injection Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.1	2025/04/14	632208-00019	Date of first issue: 2016/05/03

---

**1. PRODUCT AND COMPANY IDENTIFICATION**

Chemical product name : Furosemide Injection Formulation

**Supplier's company name, address and phone number**

Company name of supplier : MSD

Address : 1-13-12, Kudan-kita, Chiyoda-ku, Tokyo, Japan

Telephone : 03-6272-1099

E-mail address : EHSDATASTEWARD@msd.com

Emergency telephone number : +1-908-423-6000

**Recommended use of the chemical and restrictions on use**

Recommended use : Veterinary product

Restrictions on use : Not applicable

---

**2. HAZARDS IDENTIFICATION****GHS classification of chemical product**

Specific target organ toxicity - : Category 2 (Kidney, Liver)  
repeated exposure

**GHS label elements**

Hazard pictograms :



Signal word : Warning

Hazard statements : H373 May cause damage to organs (Kidney, Liver) through prolonged or repeated exposure.

Precautionary statements :

**Prevention:**

P260 Do not breathe mist or vapours.

**Response:**

P314 Get medical advice/ attention if you feel unwell.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Furosemide Injection Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.1	2025/04/14	632208-00019	Date of first issue: 2016/05/03

**Other hazards which do not result in classification**

None known.

**3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)	ENCS No.
Furosemide	54-31-9	$\geq 1 - < 10$	9-377

**4. FIRST AID MEASURES**

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Get medical attention if symptoms occur.
In case of eye contact	: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: May cause damage to organs through prolonged or repeated exposure.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

**5. FIREFIGHTING MEASURES**

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Nitrogen oxides (NO <sub>x</sub> ) Carbon oxides Sulphur oxides

**Furosemide Injection Formulation**

Version	Revision Date:	SDS Number:	Date of last issue:
7.1	2025/04/14	632208-00019	2024/09/28
			Date of first issue: 2016/05/03

Chlorine compounds

- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

**6. ACCIDENTAL RELEASE MEASURES**

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**7. HANDLING AND STORAGE****Handling**

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe mist or vapours.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.

**Furosemide Injection Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.1	2025/04/14	632208-00019	Date of first issue: 2016/05/03

Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact : Oxidizing agents  
Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**Storage**

Conditions for safe storage : Keep in properly labelled containers.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

Packaging material : Unsuitable material: None known.

**8. EXPOSURE CONTROLS/PERSONAL PROTECTION****Threshold limit value and permissible exposure limits for each component in the work environment**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Concentration standard / Permissible concentration	Basis
Furosemide	54-31-9	TWA	200 µg/m <sup>3</sup>	Internal
		TWA	OEB 2 (>=100 - 1000 µg/m <sup>3</sup> )	Internal

**Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Laboratory operations do not require special containment.

**Personal protective equipment**

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the rec-

## Furosemide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.1	2025/04/14	632208-00019	Date of first issue: 2016/05/03

Filter type	: Recommended guidelines, use respiratory protection.
Hand protection	: Particulates type
Material	: Chemical-resistant gloves
Eye protection	: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	: Work uniform or laboratory coat.

**9. PHYSICAL AND CHEMICAL PROPERTIES**

Physical state	: Aqueous solution
Colour	: yellow
Odour	: No data available
Odour Threshold	: No data available
Melting point/freezing point	: No data available
Boiling point, initial boiling point and boiling range	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Lower explosion limit and upper explosion limit / flammability limit	
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Flash point	: No data available
Decomposition temperature	: No data available
pH	: No data available
Evaporation rate	: No data available
Auto-ignition temperature	: No data available
Viscosity	
Viscosity, kinematic	: No data available
Solubility(ies)	

**Furosemide Injection Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.1	2025/04/14	632208-00019	Date of first issue: 2016/05/03

---

Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Vapour pressure	:	No data available
Density and / or relative density	:	
Relative density	:	No data available
Density	:	No data available
Relative vapour density	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Particle characteristics	:	
Particle size	:	Not applicable

---

**10. STABILITY AND REACTIVITY**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

**11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

**Acute toxicity**

Not classified based on available information.

**Components:****Furosemide:**

Acute oral toxicity	:	LD50 (Rat): 2,600 mg/kg LD50 (Dog): 2,000 mg/kg
---------------------	---	--

**Furosemide Injection Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.1	2025/04/14	632208-00019	Date of first issue: 2016/05/03

---

LD50 (Rabbit): 800 mg/kg

Acute toxicity (other routes of administration) : LD0 (Humans): 6 - 29 mg/kg  
Application Route: IntravenousLD50 (Rat): 800 mg/kg  
Application Route: Intravenous**Skin corrosion/irritation**

Not classified based on available information.

**Serious eye damage/eye irritation**

Not classified based on available information.

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Furosemide:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: In vitro mammalian cell gene mutation test Test system: mouse lymphoma cells Result: positive
		Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro) Test system: mammalian liver cells Result: negative
		Test Type: Chromosome aberration test in vitro Test system: Chinese hamster ovary cells Result: positive
		Test Type: In vitro sister chromatid exchange assay in mammalian cells Test system: Chinese hamster cells Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion

**Furosemide Injection Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.1	2025/04/14	632208-00019	Date of first issue: 2016/05/03

---

Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)

Species: Chinese hamster

Application Route: Ingestion

Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****Furosemide:**

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	104 weeks
LOAEL	:	16 mg/kg body weight
Result	:	equivocal

Species	:	Mouse
Application Route	:	Ingestion
Exposure time	:	2 Years
LOAEL	:	91 mg/kg body weight
Result	:	positive

**Reproductive toxicity**

Not classified based on available information.

**Components:****Furosemide:**

Effects on fertility	:	Test Type: One-generation reproduction toxicity study
		Species: Rat
		Application Route: Ingestion
		General Toxicity - Parent: NOAEL: 90 mg/kg body weight
		Result: No effects on reproduction parameters

Test Type: One-generation reproduction toxicity study

Species: Mouse

Application Route: Ingestion

General Toxicity - Parent: NOAEL: 200 mg/kg body weight

Result: No effects on reproduction parameters

Effects on foetal development	:	Test Type: Fertility/early embryonic development
		Species: Rat
		Application Route: Ingestion
		General Toxicity Maternal: LOAEL: 50 mg/kg body weight
		Developmental Toxicity: NOAEL: 300 mg/kg body weight
		Result: No embryotoxic effects, No teratogenic effects

Test Type: Fertility/early embryonic development



**Furosemide Injection Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.1	2025/04/14	632208-00019	Date of first issue: 2016/05/03

---

Species: Mouse  
Application Route: Ingestion  
General Toxicity Maternal: LOAEL: 25 mg/kg body weight  
Result: Maternal toxicity observed., Fetal effects

Test Type: Fertility/early embryonic development  
Species: Rabbit  
Application Route: Ingestion  
General Toxicity Maternal: LOAEL: <= 12 mg/kg body weight  
Developmental Toxicity: LOAEL: 12.5 mg/kg body weight  
Result: Maternal toxicity observed., Reduced number of viable fetuses

Test Type: Fertility/early embryonic development  
Species: Rabbit  
Application Route: Ingestion  
General Toxicity Maternal: LOAEL: 15 mg/kg body weight  
Result: Maternal toxicity observed., No effects on foetal development

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

May cause damage to organs (Kidney, Liver) through prolonged or repeated exposure.

**Components:****Furosemide:**

Exposure routes	: Ingestion
Target Organs	: Kidney
Assessment	: Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less.

**Repeated dose toxicity****Components:****Furosemide:**

Species	: Dog
NOAEL	: 4 mg/kg
LOAEL	: 8 mg/kg
Application Route	: Ingestion
Exposure time	: 12 Months
Target Organs	: Kidney
Symptoms	: Blood disorders
Remarks	: Significant toxicity observed in testing

**Aspiration toxicity**

Not classified based on available information.

**Furosemide Injection Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.1	2025/04/14	632208-00019	Date of first issue: 2016/05/03

---

**Experience with human exposure****Components:****Furosemide:**

Inhalation	:	Remarks: May be harmful if inhaled.
Skin contact	:	Remarks: May irritate skin.
Eye contact	:	Remarks: May cause eye irritation.
Ingestion	:	Symptoms: Kidney disorders, Headache, electrolyte imbalance, dry mouth, hearing loss, Irregular cardiac activity, Gastrointestinal disturbance, hypotension

---

**12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Furosemide:**

Toxicity to fish	:	LC50 : 500 mg/l Exposure time: 96 h
------------------	---	--

**Persistence and degradability**

No data available

**Bioaccumulative potential****Components:****Furosemide:**

Partition coefficient: n-octanol/water	:	log Pow: 2.03
--	---	---------------

**Mobility in soil**

No data available

**Hazardous to the ozone layer**

Not applicable

**Other adverse effects**

No data available

---

**13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues	:	Dispose of in accordance with local regulations. Do not dispose of waste into sewer.
Contaminated packaging	:	Empty containers should be taken to an approved waste han-

---

**Furosemide Injection Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.1	2025/04/14	632208-00019	Date of first issue: 2016/05/03

ding site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

**14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Environmentally hazardous	:	no

**IATA-DGR**

UN/ID No.	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Packing instruction (cargo aircraft)	:	Not applicable
Packing instruction (passenger aircraft)	:	Not applicable

**IMDG-Code**

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
EmS Code	:	Not applicable
Marine pollutant	:	Not applicable

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**National Regulations**

Refer to section 15 for specific national regulation.

**Special precautions for user**

Not applicable

**15. REGULATORY INFORMATION****Related Regulations****Fire Service Law**

Not applicable to dangerous materials / designated flammables.

**Furosemide Injection Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.1	2025/04/14	632208-00019	Date of first issue: 2016/05/03

---

**Chemical Substance Control Law**

Not applicable for Specified Chemical Substance, Monitoring Chemical Substance and Priority Assessment Chemical Substance.

**Industrial Safety and Health Law****Harmful Substances Prohibited from Manufacture**

Not applicable

**Harmful Substances Required Permission for Manufacture**

Not applicable

**Substances Prevented From Impairment of Health**

Not applicable

**Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity**

Not applicable

**Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity**

Not applicable

**Substances Subject to be Notified Names**

Not applicable

**Substances Subject to be Indicated Names**

Not applicable

**Skin and Eye Damage Substances (ISHL MO Art. 594-2)**

Not applicable

**Carcinogenic Substances (Article 577-2 of the Occupational Health and Safety Regulations)**

Not applicable

**Ordinance on Prevention of Hazards Due to Specified Chemical Substances**

Not applicable

**Ordinance on Prevention of Lead Poisoning**

Not applicable

**Ordinance on Prevention of Tetraalkyl Lead Poisoning**

Not applicable

**Ordinance on Prevention of Organic Solvent Poisoning**

Not applicable

**Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)**

Not applicable

**Poisonous and Deleterious Substances Control Law**

Not applicable

**Furosemide Injection Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.1	2025/04/14	632208-00019	Date of first issue: 2016/05/03

---

**Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof**

Not applicable

**High Pressure Gas Safety Act**

Not applicable

**Explosive Control Law**

Not applicable

**Vessel Safety Law**

Not regulated as a dangerous good

**Aviation Law**

Not regulated as a dangerous good

**Marine Pollution and Sea Disaster Prevention etc Law**

Bulk transportation : Not classified as noxious liquid substance

Pack transportation : Not classified as marine pollutant

**Narcotics and Psychotropics Control Act**

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)

Not applicable

**Waste Disposal and Public Cleansing Law**

Industrial waste

**The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

---

**16. OTHER INFORMATION****Further information**Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : yyyy/mm/dd

**Full text of other abbreviations**

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for

**Furosemide Injection Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.1	2025/04/14	632208-00019	Date of first issue: 2016/05/03

---

Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN